These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 16137750)

  • 21. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
    Cass I; Holschneider C; Datta N; Barbuto D; Walts AE; Karlan BY
    Obstet Gynecol; 2005 Dec; 106(6):1327-34. PubMed ID: 16319259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
    Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
    Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
    Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
    Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
    Rabban JT; Krasik E; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Dec; 33(12):1878-85. PubMed ID: 19898224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
    Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
    Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic oophorectomy in women at increased cancer risk.
    Domchek SM; Rebbeck TR
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
    Vicus D; Shaw PA; Finch A; Rosen B; Murphy J; Armel S; Sun P; Narod SA
    Gynecol Oncol; 2010 Sep; 118(3):295-8. PubMed ID: 20722102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation.
    Rabban JT; Mackey A; Powell CB; Crawford B; Zaloudek CJ; Chen LM
    Gynecol Oncol; 2011 Jun; 121(3):466-71. PubMed ID: 21353295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.
    Hirst JE; Gard GB; McIllroy K; Nevell D; Field M
    Int J Gynecol Cancer; 2009 Jul; 19(5):826-9. PubMed ID: 19574767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA2 germline mutations in primary cancer of the fallopian tube.
    Casarsa S; Puglisi F; Baudi F; De Paola L; Venuta S; Piga A; Di Loreto C; Marchesoni D; D'Elia AV; Damante G
    Oncol Rep; 2004 Aug; 12(2):313-6. PubMed ID: 15254695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
    Leeper K; Garcia R; Swisher E; Goff B; Greer B; Paley P
    Gynecol Oncol; 2002 Oct; 87(1):52-6. PubMed ID: 12468342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
    Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Lubsen-Brandsma L; Massuger LF; Mourits MJ; Gaarenstroom KN; van Dorst EB; van der Putten H; Boonstra H; Aaronson NK
    J Clin Oncol; 2007 Jan; 25(3):301-7. PubMed ID: 17235045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    Cheng A; Li L; Wu M; Lang J
    Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
    Mingels MJ; Roelofsen T; van der Laak JA; de Hullu JA; van Ham MA; Massuger LF; Bulten J; Bol M
    Gynecol Oncol; 2012 Oct; 127(1):88-93. PubMed ID: 22710074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
    Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
    Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
    Callahan MJ; Crum CP; Medeiros F; Kindelberger DW; Elvin JA; Garber JE; Feltmate CM; Berkowitz RS; Muto MG
    J Clin Oncol; 2007 Sep; 25(25):3985-90. PubMed ID: 17761984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.